An interventional study of No reduction and Closed Reduction in Distal Radius Fracture, Casting and Closed Reduction, sponsored by Tampere University Hospital. Recruiting at 11 sites in 4 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Tampere University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
DISCLOSE trial is a randomized controlled trial including 532 participants with low-energy distal radius fractures. The primary objective is to evaluate whether casting without prior closed reduction is equivalent to casting following closed reduction with respect to wrist-related pain and disability, as measured by the Patient-Rated Wrist Evaluation (PRWE) score at 12 months, in patients aged 65 years or older with a displaced distal radius fracture.
Interventions:
No reduction: In the no reduction group, a dorsal cast is applied to the patient's wrist after the initial radiograph. Following casting, a control radiograph will be taken. Active range of motion exercises for the fingers and light use of the hand are recommended immediately.
Closed reduction: Distal radius fracture reduction is performed in the emergency department under local anaesthetic, with lidocaine infiltrated into the fracture site. Closed reduction is performed by the on-call physician who is responsible for the patient's treatment. Post-reduction radiographs are then taken to assess fracture alignment, although the findings do not influence the treatment of the patient. The follow-up visits, cast removal, and exercise protocol are identical to those inof the no reduction group.
In both groups, the cast will be removed after 5 weeks at either the health center or the hospital's outpatient clinic, in accordance with the local treatment protocol. Following cast removal, patients will be advised to resume everyday use of the injured wrist without restrictions. No radiographs will be taken during the casting period or before the 3-month follow-up.
Observational arm (not part of the randomised equivalence trial): Eligible patients who decline participation in the randomisation will be offered the opportunity to join an observational group. The patients will receive standard care (closed reduction and casting) and will provide consent for follow-up. Reduction of the DRF is performed in the emergency department and post-reduction radiographs will be taken. The observational groups will be treated according to local treatment protocols. Patients in the observational cohort will be followed at the same time points using the same outcome measures as the randomised group. Study follow-up of the observational group will be organized remotely.
Blinding: Recruiting will start at July 2025.Due to the nature of the intervention, the participants will not be blinded. Recruiting personnel will only have access to the randomisation module within the electronic REDCap (Research Electronic Data Capture, https://www.project-redcap.org/) software. The outcome assessors (study nurse or orthopaedic resident or specialist) who collect the baseline data and outcome measures from the follow-up visits will be blinded to the randomisation result. Furthermore, the study personnel involved in the follow-up visits will remain blinded to the randomisation results, as the results will be hidden in REDCap.
Follow-up: Participants will meet a research personnel or coordinator study nurse at the 3-month and 12-month time points. At the 3-month time point, radiographs will be taken. Thereafter, no additional radiographic follow-ups will be organized. Follow-up appointments will be carried out according to the preferences of the participants. For example, all patients will be invited to attend an in-person follow-up visit; however, if this is unsuitable, the follow-up will be conducted remotely via telephone or email link by a blinded study nurse. In the remote option, the accelerometer wristbands will be sent to the participants by regular mail. By offering a remote option, we aim to minimise the number of participants unavailable for follow-up. The participants will receive follow-up questionnaires via email or regular mail prior to their follow-up appointment. If they decline to complete the questionnaires, outcomes will be collected via a telephone interview. The research data will be saved in a database using the online patient management program REDCap. The 5-year follow-up will be conducted by phone.
Rehabilitation: All patients presenting with unsettling symptoms will undergo physiotherapy rehabilitation for up to one year, as in standard care. If the symptoms do not improve during this period, the patient will be referred to an orthopaedic surgeon or hand surgeon for further evaluation where necessary procedures, such as a computed tomography (CT) scan and, in some cases corrective osteotomy, will be considered.
Sample size and power considerations: The sample size was determined based on an equivalence design with an equal allocation ratio (1:1). Based on the MID for PRWE of 11.5 points, the equivalence margin was set at 6 points. This represents the maximum acceptable difference in means between the groups to still be able to consider the groups as equivalent. Based on the findings of previous studies, the standard deviation of the outcome (PRWE) variable was estimated to be 21.9. Using these parameter estimates, a total sample size of 532 participants (266 per group) will provide 90% power to demonstrate equivalence between groups on the primary endpoint, assuming a true mean difference of \< 0.01, a common standard deviation of 21, and equivalence margins of -6 to 6 on the PRWE score. The calculation was based on a 2-sided 90% confidence interval (α = 0.05) and used the exact method for two-sample means under normal distribution assumptions.
331 studies on the registry are indexed under Wrist Fractures; 71 are open to participants now.
This study's planned enrollment of 532 is above the median of 64 across 266 interventional studies indexed under Wrist Fractures.
Browse Wrist Fractures studies →Tampere University Hospital is the lead sponsor of 212 studies on the registry; 56 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Closed reduction and casting after distal radius fracture
Procedure: Closed Reduction · Other: Casting
Casting without reduction after distal radius fracture
Procedure: No reduction · Other: Casting
No reduction
Closed reduction
Dorsal cast
PRWE
Primary outcome will be the Patient Rated Wrist Evaluation (PRWE) at 12 months. PRWE is a 15-item questionnaire designed to measure wrist pain and disability in activities of daily living. The questionnaire consists of two subscales (pain and function), and the score ranges from 0 (no disability) to 100 (severe disability).
Time frame: 12 months
Pain (NRS)
The Numeric Rating Scale (NRS) is a subjective measure of acute pain. The Numeric Rating Scale (NRS) for Pain is a validated 11-point numerical rating scale for acute and chronic pain with terminal descriptors of 0 (no pain) and 10 (worst pain possible). Patients will be asked to evaluate their perceived pain during the previous 7 days.
Time frame: 3 months and 12 months
PASS
Patient satisfaction will be measured using the patient-acceptable symptom state (PASS). The questionnaire includes the following question: Considering all the different ways your injury is affecting you, if you would remain in this state, do you feel that your current state is satisfactory (Yes/No)?
Time frame: 3 months and 12 months
EQ-5D-5L- Quality of life
EuroQol 5-dimension 5-level health-related quality of life questionnaire (EQ-5D-5L). It consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. We will use the EQ-5D-5L Index score, which is calculated based on each dimension using population-specific preference weights and will be reported on a scale from less than 0 to 1.
Time frame: 3 months and 12 months
Serious adverse events
Serious adverse events include, but are not limited to: late surgical interventions such as corrective osteotomy or internal fixation due to symptomatic nonunion; tendon repair; carpal tunnel release; acute nerve injury confirmed by electroneuromyography; and any other adverse event that results in hospitalisation, prolongation of existing hospitalisation, is life-threatening, or leads to persistent or significant disability (for example CRPS) or incapacity. Serious adverse events will be assessed at 3- and 12-months timepoints.
Time frame: 3 months and 1 year
Cosmesis
Participants are asked to complete questionnaire about wrist cosmesis. Does the appearance of the wrist bother you? (yes/no)
Time frame: 3 months
Radiographic measurements
Radiographic parameters will be collected from radiographs taken at baseline and after casting. Control radiographs will be taken at the 3-month time point where the loss of reduction is measured. Radiographic measurements will include dorsal angulation (degrees), ulnar variance (mm), radial inclination (degrees), step-off in the articular surface (mm), and intra-articular gap (mm)
Time frame: Baseline and 3 months
Tri-Axial Accelerometry (Published separately)
The upper-limb physical activity of the participants will be measured using a tri-axial (Axivity Ltd, Newcastle upon Tyne, UK) accelerometer. Activity is divided into 4 activity levels (inactive, light, moderate and vigorous), and also sleeping time is counted and recorded.
Time frame: 3 and 12 months
Cost-effectiveness (Published separately)
Included unit cost components include hospital stays and outpatient visits, including imaging, surgical and anesthetic procedures, physiotherapy, complication management and re-operations and cast changes. Costs will be obtained directly from patients through questionnaires administered at the 3 and 12 month follow-up, and from medical records. Cost data will be derived from the NordDRG classification system. Using the mean costs and mean health outcomes for each cohort, the incremental cost per quality-adjusted life-year (QALY) gained will be calculated.
Time frame: 12 months
5 year exploratory endpoint (Published separately)
PRWE, pain (NRS), quality of life, patient satisfaction (PASS), serious adverse events, and mortality will be assessed at 5 years and are exploratory endpoints.
Time frame: 5-year
Plan to share: No — IPD will not be shared due to restrictions under Finnish data protection regulations, which limit the sharing of sensitive personal data, even in de-identified form, without specific consent or legal basis.
Started Aug 2025 (actual). Primary completion is estimated for Jul 2029, 47 months after the start.
Of 128 non-industry interventional studies with no phase under Wrist Fractures, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 47 months is above that.
Counting every sponsor, half of 129 studies reached it within 24 months; a quarter within 16 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.